WO 2014/120981 Al 7 August 2014 (07.08.2014) P O P C T

Total Page:16

File Type:pdf, Size:1020Kb

WO 2014/120981 Al 7 August 2014 (07.08.2014) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/120981 Al 7 August 2014 (07.08.2014) P O P C T (51) International Patent Classification: Gilead Pharmasset LLC, 333 Lakeside Drive, Foster City, A61K 9/16 (2006.01) A61K 31/501 (2006.01) California 94404 (US). A61K 9/20 (2006.01) A61K 31/513 (2006.01) (74) Agents: TANNER, Lorna L. et al; Sheppard Mullin (21) International Application Number: Richter & Hampton Lip, 379 Lytton Avenue, Palo Alto, PCT/US2014/013953 California 94301-1479 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 30 January 2014 (30.01 .2014) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/759,320 31 January 2013 (3 1.01.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/772,292 4 March 2013 (04.03.2013) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 61/828,899 30 May 2013 (30.05.2013) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 61/870,729 27 August 2013 (27.08.2013) US TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 61/897,793 30 October 20 13 (30. 10.20 13) US ZW. 61/907,332 2 1 November 2013 (21. 11.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: GILEAD PHARMASSET LLC [US/US]; kind of regional protection available): ARIPO (BW, GH, 333 Lakeside Drive, Foster City, California 94404 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (72) Inventors: CHAL, Ben; c/o Gilead Pharmasset LLC, 333 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Lakeside Drive, Foster City, California 94404 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, MOGALIAN, Erik; c/o Gilead Pharmasset LLC, 333 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Lakeside Drive, Foster City, California 94404 (US). PAK- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, DAMAN, Rowchanak; c/o Gilead Pharmasset LLC, 333 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Lakeside Drive, Foster City, California 94404 (US). KM, ML, MR, NE, SN, TD, TG). OLIYAI, Reza; c/o Gilead Pharmasset LLC, 333 Lakeside Published: Drive, Foster City, California 94404 (US). STEFANIDIS, — with international search report (Art. 21(3)) Dimitrios; c/o Gilead Pharmasset LLC, 333 Lakeside Drive, Foster City, California 94404 (US). ZIA, Vahid; c/o 00 © o (54) Title: COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS (57) Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application Number 61/759,320, filed on January 31, 2013, U.S. Provisional Application Number 61/772,292, filed on March 4, 2013, U.S. Provisional Application Number 61/828,899, filed on May 30, 2013, U.S. Provisional Application Number 61/870,729, filed on August 27, 2013, U.S. Provisional Application Number 61/897,793, filed on October 30, 2013, and U.S. Provisional Application Number 61/907,332, filed on November 21, 2013, the entirety of which are all incorporated herein by reference. BACKGROUND [0002] Hepatitis C is recognized as a chronic viral disease of the liver which is characterized by liver disease. Although drugs targeting the liver are in wide use and have shown effectiveness, toxicity and other side effects have limited their usefulness. Inhibitors of hepatitis C virus (HCV) are useful to limit the establishment and progression of infection by HCV as well as in diagnostic assays for HCV. [0003] Ledipasvir is a selective inhibitor of non-structural protein 5A (NS5A), which has been described previously (see, for example, WO 2010/132601). The chemical name of ledipasvir is (l-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5- aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-lH-benzoimidazol-2-yl]-2-aza- bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester. [0004] Sofosbuvir (SOF) is a selective inhibitor of non-structural protein 5B (NS5B) (see, for example, WO 2010/132601 and U.S. Patent 7,964,580). The chemical name of sofosbuvir is (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin- 1(2H)-yl)-4-fluoro-3 -hydroxy-4-methyltetrahydrofuran-2- yl)methoxy)(phenoxy)phosphoryl)amino) propanoate. SUMMARY [0005] The present disclosure provides, in some embodiments, a pharmaceutical composition comprising ledipasvir in a substantially amorphous form and sofosbuvir in a substantially crystalline form. [0006] Ledipasvir has the chemical name of (l-{3-[6-(9,9-difluoro-7-{2-[5-(2- methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H- fluoren-2-yl)-lH-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl- propyl)-carbamic acid methyl ester, and has the following chemical formula: [0007] Sofosbuvir (SOF) has the chemical name of (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)- 5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2- yl)methoxy)(phenoxy)phosphoryl)amino)propanoate and has the following chemical formula: [0008] In some embodiments, provided is a pharmaceutical composition comprising: a) an effective amount of ledipasvir, wherein ledipasvir is substantially amorphous; and b) an effective amount of sofosbuvir wherein sofosbuvir is substantially crystalline. [0009] Further embodiments of the disclosure relate to pharmaceutical dosage forms and tablets. The disclosure also provides methods for using the combination in the treatment of hepatitis C. BRIEF DESCRIPTION OF THE DRAWINGS [0010] FIG. 1 is a XRPD pattern of the solid dispersion formulation of ledipasvir comprising copovidone in a drug:polymer ratio of 1:1. As shown by the XRPD, the solid dispersion is in the amorphous state. [0011] FIG. 2 is a modulated differential scanning calorimetry (DSC) curve of the solid dispersion of ledipasvir comprising copovidone in a drug:polymer ratio of 1:1. The glass transition temperature of the solid dispersion is about 140 °C. [0012] FIG. 3 shows a solid state characterization of the solid dispersion formulation of ledipasvir comprising copovidone in a drug:polymer ratio of 1:1by solid state nuclear magnetic resonance (SS-NMR). [0013] FIG. 4 is a Fourier-transformed Raman spectra of the solid dispersion of ledipasvir comprising copovidone in a drug:polymer ratio of 1:1. [0014] FIG. 5 shows the dissolution of sofosbuvir in the sofosbuvir (400 mg)/ledipasvir (90 mg) combination described in Example 7. [0015] FIG. 6 shows the dissolution of ledipasvir in the sofosbuvir (400 mg)/ledipasvir (90 mg) combination formulation described in Example 3. [0016] FIG. 7A-D shows the HCV RNA levels during 1 weeks of treatment and 24 weeks post-treatment for treatment na ve (FIG. 7A) or null responder (FIG. 7B) patients treated with sofosbuvir (SOF) and ribavirin (RBV) and for treatment na ve (FIG. 7C) or null responder (FIG. 7D) patients treated with sofosbuvir (SOF), ledipasvir and ribavirin (RBV). This data and experimental method are further described in Example 5. [0017] FIG. 8A-B present charts to show that all three formulations had comparable dissolution performance, similar to that of the single-agent controls. This is more thoroughly described in Example 7. [0018] FIG. 9 presents the pH-solubility profile of ledipasvir at room temperature (RT). The line is the nonlinear least-square regression fit using equation PK L PH (pKal+pKa2 2 pH) µ π ST = SO [(i+i 0 - +10 - - )] with an intrinsic solubility (S0) of 0.04 and a weakly basic pKal and pKa2 values of 5.0 and 4.0, respectively. This is more thoroughly described in Example 8. [0019] FIG. 10 shows the study design for treatment naive (non-cirrhotic) and for null responders (50% cirrhotic) for patients treated with a fixed dose combination of sofosbuvir (SOF) and ledipasvir, with and without ribavirin (RBV) for 8 and 12 weeks. The data and experimental method are described in Example 9. [0020] FIG. 11 shows the results for treatment naive (non-cirrhotic) and for null responders (50%> cirrhotic) for patients treated with a fixed dose combination of sofosbuvir (SOF) and ledipasvir, with and without ribavirin (RBV) for 8 and 1 weeks. This data and experimental method are further described in Example 9. DETAILED DESCRIPTION 1. Definitions [0021] As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise. [0022] As used herein, the term "about" used in the context of quantitative measurements means the indicated amount ± 10%, or alternatively ± 5%, or ± 1%. For example, with a ± 10% range, "about 2:8" can mean 1.8-2.2:7.2-8.8.
Recommended publications
  • UNO Template
    26 November 2013 Americas/United States Equity Research Biotechnology Global Biotech & Pharma: The HCV Revolution - Edition 2 Research Analysts COMMENT Ravi Mehrotra PhD 212 325 3487 [email protected] What Is The N Number: Keeping An Eye On Vamil Divan, MD 212 538 5394 Potential Longer Term Pricing Disruption [email protected] Koon Ching PhD ■ No pricing disruption expected in the near-term, but potential exists in 212 325 6286 the medium- to long-term. OK this is somewhat obvious, but bear with us: [email protected] Value/NPV = Price x Mkt Share x Mkt Size x Mkt Longevity. This is the Bruce Nudell PhD second note in our "The HCV Revolution" series. HCV is clearly a highly 212 325 9122 competitive therapeutic area with many players vying for their share of the [email protected] potentially >$15B/year HCV market. We previously addressed immediate- European Pharma Team 44 207 888 0304 term pricing of next-generation regimens, specifically for Sofosbuvir (LINK). [email protected] In this note, we simply highlight the potential number of competing all-oral, Ronak H. Shah, Pharm.D., CFA IFN-free regimens, and timing of key data, in HCV (Exhibits 1-7). The 212 325 9799 number of ultimate competitors has important implications for the HCV [email protected] market. In our view, in a HCV market with up to 4−5 players, we expect Lee Kalowski "normal drug rules" to apply: i.e. the order to market, overall clinical profile of 212 325 9683 drug, and commercial prowess will primarily dictate market share, with price [email protected] used as a tool but not in a "disruptive" way.
    [Show full text]
  • HCV Eradication with Direct Acting Antivirals (Daas)?
    HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d’Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. [email protected] HCV eradication with direct acting antivirals (DAAs)? HCV replication HCV genome and DAAs targets NS3 inhibitors NS5A inhibitors NS5B inhibitors Take home messages HCV viral cycle Asselah et al. Liver Int. 2015;35 S1:56-64. Direct acting antivirals 5’NTR Structural proteins Nonstructural proteins 3’NTR Metalloprotease Envelope Serine protease Glycoproteins RNA Capsid RNA helicase Cofactors Polymerase C E1 E2 NS1 NS2 NS3 NS4A NS4B NS5A NS5B Protease Inhibitors NS5A Inhibitors Polymerase Inhibitors Telaprevir Daclatasvir Nucs Non-Nucs Boceprevir Ledipasvir Simeprevir ABT-267 Sofosbuvir ABT-333 Faldaprevir GS-5816 VX-135 Deleobuvir Asunaprevir Direct Acting Antivirals: 2015 Asselah et al. Liver Int. 2015;35 S1:56-64. Genetic barrier for HCV direct acting antivirals High Nucleos(t)ide 1 mutation= high cost to Analog Inhibitors fitness, 2-3 additional mutations to increase fitness 2 st generation Protease Inhibitors n Non Nucleos(t)ide Analog Inhibitors : NS5 A Inhibitors 1 st generation Protease Inhibitors 1 mutation= low cost to fitness Low Halfon et al. J Hepatol 2011. Vol 55(1):192-206. HCV protease inhibitors (PI) Inhibit NS3/NS4A serine protease responsible for the processing of the polyprotein 1st generation 1st generation, 2nd wave 2nd generation Resistance low low high barrier Genotype activity 1: 1 a< 1b All except 3 all Drug drug Important Less Less interaction Drugs Boceprevir Simeprevir (Janssen) MK-5172 Telaprevir Faldaprevir (BI) ACH-2684 Paritaprevir (ABT-450)/r (AbbVie) Vedroprevir (Gilead) Vaniprevir (Merck) Sovaprevir (Achillion) Asunaprevir (BMS) NS3/NS4A structure Repositioning of helicase domain Self cleavage Lipid Bilayer Inactive Insertion of the Active carboxy-terminal tail Bartenschlager et al.
    [Show full text]
  • Diapositiva 1
    Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic, Higher SVR, Eventually Oral for all patients SVR: 70-80% ≥ 90% ≥ 90% 2013 2014 2015 Genotype 2&3 Genotype 2 Genotypes 1-6 P/R SOF+RBV 12 weeks SOF+LPV ± RBV Genotypes 1 Genotype 3 ABT-450+ABT-267+ Telaprevir + P/R SOF+RBV 24 weeks ABT- 333 +RBV Boceprevir + P/R Genotypes 1-4 DCV+ASU SOF+ P/R SOF+DCV Genotypes 1&4 SMV+ P/R HCV Resistance to DAA During DAA-based treatment: ■ Rapid selection of resistance mutation may occur, eventually leading to viral break-through. Kieffer et al. Hepatology 2007; 46:631-9 Pilot-Matias et al. 46th EASL 2011, Abs1107 ■ Several changes at different positions at the NS3 protease, NS5B polymerase, and NS5A protein have been associated with loss of susceptibility to DAAs. Sarrazin et al. Gastroenterology 2010;138:447-62 MainTable 2. Main characteristics characteristics of the genotype of theactivity genotypeand resistance of DAA activity classes. and resistance of DAA classes. Genotype activity Resistance Key resistance mutations NS3 ■ First PI generation: genotypes 1 (1b >1a) Low genetic barrier First PI generation: protease (Telaprevir & Boceprevir) High cross-resistance G1a: R155K, V36M inhibitors G1b: V36M, T54A/S, A156T ■ Second wave and second PI generation: across all but genotype 3 (D168Q) Second wave and second PI generation: (Simeprevir, faldaprevir, vaniprevir, F43S, Q80K, R155K, D168A/E/H/T/V asunaprevir, sovaprevir, MK-5172, ACH-2684) NS5 Across all genotypes High genetic barrier Sofosbuvir*: nucleos(ti)de High cross-resistance G1a: S282T+(I434M) Sofosbuvir displays less antiviral activity G1b: S282T analogues againts genotypes 3 (treatment duration 24 G2a: S282T+(T179A, M289L, I293L, inhibitors weeks of sofosbuvir+RBV).
    [Show full text]
  • Twelve-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir And
    bs_bs_banner doi:10.1111/jgh.14096 HEPATOLOGY Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study Jia-Horng Kao,* Min-Lung Yu,† Chi-Yi Chen,‡ Cheng-Yuan Peng,§ Ming-Yao Chen,¶ Huoling Tang,** Qiaoqiao Chen** and Jinzi J Wu** *Graduate Institute of Clinical Medicine and Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, ¶Division of Gastroenterology, Department of Internal Medicine, Taipei Medical University Shuang Ho Hospital, Taipei, †Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, ‡Division of Gastroenterology, Department of Internal Medicine, Chia-Yi Christian Hospital, Chiayi, and §Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; and **Ascletis BioScience Co., Ltd., Hangzhou, China Key words Abstract danoprevir, efficacy, hepatitis C, interferon free, ravidasvir. Background and Aim: The need for all-oral hepatitis C virus (HCV) treatments with higher response rates, improved tolerability, and lower pill burden compared with Accepted for publication 9 January 2018. interferon-inclusive regimen has led to the development of new direct-acting antiviral agents. Ravidasvir (RDV) is a second-generation, pan-genotypic NS5A inhibitor with high Correspondence barrier to resistance. The aim of this phase 2 study (EVEREST study) was to assess the ef- Jia-Horng Kao, Graduate Institute of Clinical ficacy and safety of interferon-free, 12-week RDV plus ritonavir-boosted danoprevir Medicine and Hepatitis Research Center, (DNVr) and ribavirin (RBV) regimen for treatment-naïve Asian HCV genotype 1 (GT1) National Taiwan University College of Medicine patients without cirrhosis. and Hospital, 7 Chung-Shan South Road, Taipei Methods: A total of 38 treatment-naïve, non-cirrhotic adult HCV GT1 patients were en- 10002, Taiwan.
    [Show full text]
  • Caracterización Molecular Del Perfil De Resistencias Del Virus De La
    ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en Programa de doctorado en Medicina Departamento de Medicina Facultad de Medicina Universidad Autónoma de Barcelona TESIS DOCTORAL Caracterización molecular del perfil de resistencias del virus de la hepatitis C después del fallo terapéutico a antivirales de acción directa mediante secuenciación masiva Tesis para optar al grado de doctor de Qian Chen Directores de la Tesis Dr. Josep Quer Sivila Dra. Celia Perales Viejo Dr. Josep Gregori i Font Laboratorio de Enfermedades Hepáticas - Hepatitis Víricas Vall d’Hebron Institut de Recerca (VHIR) Barcelona, 2018 ABREVIACIONES Abreviaciones ADN: Ácido desoxirribonucleico AK: Adenosina quinasa ALT: Alanina aminotransferasa ARN: Ácido ribonucleico ASV: Asunaprevir BOC: Boceprevir CCD: Charge Coupled Device CLDN1: Claudina-1 CHC: Carcinoma hepatocelular DAA: Antiviral de acción directa DC-SIGN: Dendritic cell-specific ICAM-3 grabbing non-integrin DCV: Daclatasvir DSV: Dasabuvir
    [Show full text]
  • Stamp-V3 1..249
    23 March 2016 Volume 23 Supplement 1 S1 Volume 23 Volume Supplement 1 P ages A1–A262 ages EUROPEAN JOURNAL OF HOSPITAL PHARMACY OF HOSPITAL JOURNAL EUROPEAN ABSTRACT BOOK 21st Congress of the EAHP 16-18 March 2016 Vienna, Austria March 2016 March Contents Volume 23 Supplement 1 | EJHP March 2016 Abstracts from the EAHP 2016 Congress A1 Clinical pharmacy A172 Other hospital pharmacy topics A104 Drug distribution A178 Pharmacokinetics and pharmacodynamics A118 Drug information and pharmacotherapy A195 Production and preparation A158 General management A214 Patient safety and risk management A167 International posters A250 Author index POSTER AWARD NOMINEES Presentations on Wednesday, 16 March, 14:00–15:30, Room 93 Time Poster number Poster nominee oral presentations Author 14:00 DD-021 Medicine supply chain of a central pharmacy: risk mapping F Charra shortage 14:10 PP-001 Contamination with cytotoxic drugs in the workplace – E Korczowska ESOP pilot study 14:20 PP-039 Double checking manipulations for complex and/or high A Alcobia Martins risk preparations 14:30 CP-055 The clinical pharmacist resolves medication related E Tudela-Lopez problems in cranio, maxillofacial and oral surgery patients 14:40 CP-085 The impact of pharmacist interventions on safety M Tovar Pozo and cost savings 14:50 CP-219 Effectiveness and safety of switching to dual antiretroviral J Luis Revuelta therapy in a treatment experienced HIV cohort 15:00 DD-027 Implementation and evaluation of an appointment based F J Alvarez Manceñido model for outpatients attended in
    [Show full text]
  • Daclatasvir in Combination with Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection with Compensated Cirrhosis
    Supplementary Online Content Muir AJ, Poordad F, Lalezare J; et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. doi:10.1001/jama.2015.3868. eAppendix This supplementary material has been provided by the authors to give readers additional information about their work. © 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eAppendix The historical threshold SVR was derived from a combined analysis in subjects treated with peg- interferon/ribavirin in combination with either sofosbuvir or simeprevir. The final historical threshold based on these SVR rates is: Cirrhotic Treatment-naive 69% Treatment-experienced 45% The treatment-naïve data is from the NEUTRINO trial for sofosbuvir, which demonstrated SVR rate of 91% (95% confidence interval 87-94%) in non-cirrhotic subjects [FDA antiviral drugs advisory committee, NDA 204671, 25 October, 2013]. Using a non-inferiority margin of 15% (in consideration for an IFN-free regimen), the threshold for non-cirrhotic subjects was calculated by subtracting the non-inferiority margin from the upper bound of the 95% confidence interval of the point estimate (94% - 15%), which is 79%. In the NEUTRINO trial, the SVR for cirrhotic subjects was 10% lower than for non-cirrhotic subjects (81% vs. 91%). Therefore, the historical threshold for cirrhotic subjects in AI443113 was determined by subtracting 10% from the historical threshold for non-cirrhotic subjects, which is 79%-10% = 69%. The prior relapse data is from trial HPC3007 for simeprevir [Forns et al Gastroenterology 2014;146:1669- 1679], and the non-responder data is from C206 study for simeprevir [FDA antiviral drugs advisory committee, NDA 205123, 24 October, 2013].
    [Show full text]
  • Original Article Randomized Study of Asunaprevir Plus Pegylated Interferon-Α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C
    Antiviral Therapy 2013; 18:885–893 (doi: 10.3851/IMP2660) Original article Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C Jean-Pierre Bronowicki1*, Stanislas Pol2, Paul J Thuluvath3, Dominique Larrey4, Claudia T Martorell5, Vinod K Rustgi6, David W Morris7, Ziad Younes8, Michael W Fried9, Marc Bourlière10, Christophe Hézode11, K Rajender Reddy12, Omar Massoud13, Gary A Abrams14, Vlad Ratziu15, Bing He16, Timothy Eley16, Alaa Ahmad17, David Cohen18, Robert Hindes19, Fiona McPhee18, Bridget Reilly16, Patricia Mendez16, Eric Hughes16 1INSERM 954, Centre Hospitalier Universitaire de Nancy, Université de Lorraine, Vandoeuvre les Nancy, France 2Université Paris Descartes, INSERM U1610 and Liver Unit, Hôpital Cochin, Paris, France 3Mercy Medical Center, Baltimore, MD, USA 4Hôpital Saint Eloi, Service d’Hépato-Gastroentérologie et Transplantation, INSERM 1040-IRB, Montpellier, France 5The Research Institute, Springfield, MA, USA 6Metropolitan Research, Fairfax, VA, USA 7Healthcare Research Consultants, Tulsa, OK, USA 8Gastro One, Germantown, TN, USA 9Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA 10Hôpital Saint Joseph, Service d’Hépato-Gastroentérologie, Marseille, France 11CHU Henri Mondor, Service d’Hépato-Gastroentérologie, Créteil, France 12Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA 13Division of Gastroenterology and Hepatology, University of Alabama at
    [Show full text]
  • ABT-450/R (Abbott) – GS-9451 (Gilead) • Second Generation (Pan-Genotype, High Barrier to Resistance) – MK-5172 (Merck) – ACH-2684 (Achillion)
    Paris Hepatitis Conference New Therapeutic Strategies Second Generation Protease inhibitors David R Nelson MD Professor and Associate Dean Director, Clinical and Translational Science Institute University of Florida Gainesville, USA Outline • HCV protease structure and drug targeting • First generation PIs – Major step forward – Major limitations • PIs in development – Second wave – Second generation • Clinical trial data – IFN-containing PI regimens – IFN-free PI containing regimens • Timelines and treatment paradigms NS3 protease targeting active site “catalytic triad” NS4A TARGETING . Substrate- and product analogs . Tri-peptides . Serine-trap inhibitors subdomain . Ketoamides (boceprevir, telaprevir) boundary . Macrocyclic inhibitors (e.g. Simeprevir, Danoprevir, Vaniprevir, etc.) zinc-finger . NS4A inhibitors Lorenz et al., Nature 2006 Kronenberger et al., Clin Liver Dis 2008 Welsch et al. Gut in press A Major Step Forward: First Generation PIs PegIFN/RBV BOC or TVR + pegIFN/RBV 100 69-83 80 63-75 40-59 60 38-44 29-40 SVR SVR (%) 40 24-29 20 7-15 5 0 Naive[1,2] Relapsers[3,4] Partial Null Responders[3,4] Responders[3,4] 1. Poordad F, et al. N Engl J Med. 2011;364:1195-1206. 2. Jacobson IM, et al. N Engl J Med. 2011;364:2405-2416. 3. Bacon BR, et al. N Engl J Med. 2011;364:1207-1217. 4. Zeuzem S, et al. N Engl J Med. 2011;364:2417-2428. 3. Bronowicki JP, et al. EASL 2012. Abstract 11. Limitations of First Generation PI-Based Therapy • Efficacy – Very dependent on the IFN response – Limited to gen 1 (1b>1a) • Low genetic barrier to
    [Show full text]
  • Documents Numérisés Par Onetouch
    19 ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE 51 8 Inter. CI. C07D 471/04 (2018.01) 11 A61K 31/519 (2018.01) N° 18435 A61P 29/00 (2018.01) A61P 31/12 (2018.01) A61P 35/00 (2018.01) FASCICULE DE BREVET D'INVENTION A61P 37/00 (2018.01) 21 Numéro de dépôt : 1201700355 73 Titulaire(s): PCT/US2016/020499 GILEAD SCIENCES, INC., 333 Lakeside Drive, 22 Date de dépôt : 02/03/2016 FOSTER CITY, CA 94404 (US) 30 Priorité(s): Inventeur(s): 72 US n° 62/128,397 du 04/03/2015 CHIN Gregory (US) US n° 62/250,403 du 03/11/2015 METOBO Samuel E. (US) ZABLOCKI Jeff (US) MACKMAN Richard L. (US) MISH Michael R. (US) AKTOUDIANAKIS Evangelos (US) PYUN Hyung-jung (US) 24 Délivré le : 27/09/2018 74 Mandataire: GAD CONSULTANTS SCP, B.P. 13448, YAOUNDE (CM). 45 Publié le : 15.11.2018 54 Titre: Toll like receptor modulator compounds. 57 Abrégé : The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido [3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them. O.A.P.I. – B.P. 887, YAOUNDE (Cameroun) – Tel. (237) 222 20 57 00 – Site web: http:/www.oapi.int – Email: [email protected] 18435 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Application Nos. 62/128397, filed March 4, 2015, and 62/250403, filed November 3, 2015, both of which are incorporated herein in their entireties for all purposes.
    [Show full text]
  • ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 Is Available in Electronic Format on the PMPRB Website
    MEDS ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 is available in electronic format on the PMPRB website. Une traduction de ce document est également disponible en français sous le titre : Veille des médicaments mis en marché, 2016 Patented Medicine Prices Review Board Standard Life Centre Box L40 333 Laurier Avenue West Suite 1400 Ottawa, ON K1P 1C1 Tel.: 1-877-861-2350 TTY 613-288-9654 Email: [email protected] Web: www.pmprb-cepmb.gc.ca ISSN 2560-6204 Cat. No.: H79-12E-PDF © Her Majesty the Queen in Right of Canada, as represented by the NPDUIS initiative of the Patented Medicine Prices Review Board, 2018 MEDS ENTRY WATCH 2016 About the PMPRB Acknowledgements The Patented Medicine Prices Review Board This report was prepared by the Patented (PMPRB) is a respected public agency that makes Medicine Prices Review Board (PMPRB) a unique and valued contribution to sustainable as part of the National Prescription Drug spending on pharmaceuticals in Canada by: Utilization Information System (NPDUIS). ~ providing stakeholders with price, cost and The PMPRB would like to acknowledge the utilization information to help them make timely contributions of and knowledgeable drug pricing, purchasing and ~ The members of the NPDUIS Advisory reimbursement decisions; and Committee for their expert oversight and ~ acting as an effective check on the patent rights guidance in the preparation of this report. of pharmaceutical manufacturers through the ~ PMPRB NPDUIS staff for their contribution responsible and efficient use of its consumer to the analytical content of the report: protection powers.
    [Show full text]
  • Daclatasvir in Combination with Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection with Compensated Cirrhosis
    Research Original Investigation Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis Andrew J. Muir, MD; Fred Poordad, MD; Jacob Lalezari, MD; Gregory Everson, MD; Gregory J. Dore, MBBS, MPH, PhD; Robert Herring, MD; Aasim Sheikh, MD; Paul Kwo, MD; Christophe Hézode, MD, PhD; Paul J. Pockros, MD; Albert Tran, MD, PhD; Joseph Yozviak, DO; Nancy Reau, MD; Alnoor Ramji, MD; Katherine Stuart, MBBS, PhD; Alexander J. Thompson, MBBS, PhD; John Vierling, MD; Bradley Freilich, MD; James Cooper, MD; Wayne Ghesquiere, MD; Rong Yang, PhD; Fiona McPhee, PhD; Eric A. Hughes, MD, PhD; E. Scott Swenson, MD, PhD; Philip D. Yin, MD, PhD Editorial page 1716 IMPORTANCE Effective and well-tolerated, interferon-free regimens are needed for treatment Author Audio Interview at of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. jama.com Related article page 1728 OBJECTIVE All-oral therapy with daclatasvir (nonstructural protein 5A [NS5A] inhibitor), asunaprevir (NS3 protease inhibitor), and beclabuvir (nonnucleoside NS5B inhibitor), with or Supplemental content at without ribavirin, was evaluated in patients with HCV genotype 1 infection and jama.com compensated cirrhosis. DESIGN, SETTING, AND PARTICIPANTS The UNITY-2 study was conducted between December 2013 and October 2014 at 49 outpatient sites in the United States, Canada, France, and Australia. Patients were treated for 12 weeks, with 24 weeks of follow-up after completion of treatment. Adult patients with cirrhosis were enrolled in 2 cohorts: HCV treatment-naive or HCV treatment-experienced. Statistical analyses were based on historical controls; there were no internal controls.
    [Show full text]